Company Description
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients.
Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.
The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy.
In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs.
Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.
| Country | United Kingdom |
| Founded | 2020 |
| IPO Date | May 28, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 76 |
| CEO | Dr. Saurabh Saha M.D., Ph.D. |
Contact Details
Address: 3rd Floor, 1 Ashley Road Altrincham, Cheshire, X0 WA14 2DT United Kingdom | |
| Phone | 44 7391 789784 |
| Website | centessa.com |
Stock Details
| Ticker Symbol | CNTA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $20.00 |
| CIK Code | 0001847903 |
| CUSIP Number | 152309100 |
| ISIN Number | US1523091007 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Saurabh Saha M.D., Ph.D. | Chief Executive Officer and Director |
| Dr. David M. Chao Ph.D. | Chief Administrative Officer |
| Dr. Antoine Yver M.D., M.Sc. | Executive Vice President and Chairman of Development |
| Dr. Gregory M. Weinhoff M.B.A., M.D. | Principal Accounting Officer and Chief Financial Officer |
| Tia L. Bush | Chief Technology and Quality Officer |
| Kristen K. Sheppard Esq., J.D. | Senior Vice President of Investor Relations and Corporate Communications |
| Iqbal J. Hussain L.L.B. | General Counsel, Chief Compliance Officer and Corporate Secretary |
| Karen M. Anderson | Chief People Officer |
| Dr. Harris L. Rotman Ph.D. | Senior Vice President of Regulatory Affairs |
| Dr. Patrick Yue M.D. | Senior Vice President of Clinical Development and Innovative Medicines |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 13, 2024 | 10-Q | Quarterly Report |
| May 13, 2024 | 8-K | Current Report |
| May 9, 2024 | ARS | Filing |
| May 9, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 26, 2024 | PRE 14A | Other preliminary proxy statements |
| Apr 25, 2024 | 424B5 | Filing |
| Apr 24, 2024 | 8-K | Current Report |
| Apr 23, 2024 | 424B5 | Filing |
| Apr 22, 2024 | 8-K | Current Report |
| Mar 28, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |